Developing new drugs to fight tuberculosis.
Optimization of novel inhibitors of mycolic acid synthesis as TB drug candidates.
This study is working on new medicines to help fight tuberculosis by targeting a specific part of the bacteria that causes it, with the goal of finding better treatments that work even against tough, drug-resistant strains.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Central Florida NIH-funded |
| Lab location | 1 site (Orlando, United States) |
| Project ID | NIH-10948553 on NIH RePORTER |
What this research studies
This research focuses on creating novel inhibitors that target mycolic acid synthesis in the bacteria causing tuberculosis (TB). By understanding the different states of the bacteria and their environments, the research aims to develop more effective antibiotic treatments that can overcome the limitations of current therapies. The approach includes testing various drug combinations to ensure they can effectively kill the bacteria while minimizing resistance. This is particularly important given the rising challenge of multidrug-resistant TB strains.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with tuberculosis, especially those who have drug-resistant strains or have difficulty tolerating current treatments.
Not a fit: Patients with non-tuberculosis related respiratory conditions or those who are not infected with Mycobacterium tuberculosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and shorter treatment options for tuberculosis, improving patient outcomes and reducing the burden of the disease.
How similar studies have performed: Previous research has shown promise in developing new antibiotics targeting mycobacterial infections, indicating that this approach has potential for success.
Where this research is happening
Orlando, United States
- University of Central Florida — Orlando, United States (Active)
Researchers
- Principal investigator: Rohde, Kyle H — University of Central Florida
- Study coordinator: Rohde, Kyle H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.